Lb Pharmaceuticals (LBRX) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about LBRX filings

Are insiders buying or selling LB Pharmaceuticals Inc Common Stock (LBRX) stock?

Neither. LB Pharmaceuticals Inc Common Stock (LBRX) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded LBRX recently?

None. No member of Congress disclosed a LBRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this LBRX smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

FMFmrQ3 2026 13FAdded$33.4M

13F: filed up to 45 days late.

Smart money on LBRX

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
- FMR LLC, added +$33.4M, holdings at Sep 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about LBRX filings

Are insiders buying or selling LB Pharmaceuticals Inc Common Stock (LBRX) stock?

Neither. LB Pharmaceuticals Inc Common Stock (LBRX) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded LBRX recently?

None. No member of Congress disclosed a LBRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this LBRX smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$33.4M

Buys/Adds (1)

FM
FMR LLC
Q3 2026 13F
$33.4M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Other smart money signals

Activist stakes, short interest & more

2 items

JC
JPMorgan ChaseLight
JPMORGAN CHASE & CO filed SC 13G/A on LB PHARMACEUTICALS INC (passive 4.30% stake)
SI
Short Interest ChangeModerate
short-volume tape softening: latest 49.9% fell 18.5pp vs 20d avg 68.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 11.2% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$1.79-11.18% miss

-$1.61 expected

Revenue

$0.00

SEC filing · No operating revenue

Next report

What the street expects next

Estimates as of Nov 11, 2026

EPS expected

-$1.89

-$2.29 to -$1.72

Estimate drift

0.32

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$1.79est. -$1.61	-11.18%miss	$0.00SEC filing	No year-ago quarter
Jun 30, 2026Reported Aug 11, 2026	-$1.71est. -$0.84	-103.57%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 12, 2026	-$0.67est. -$0.70	+3.61%beat	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Mar 26, 2026	-$0.45est. -$0.32	-40.63%miss	$0.00Alpha Vantage	No year-ago quarter
Sep 30, 2025Reported Nov 6, 2025	-$0.61est. -$0.28	-117.86%miss	$0.00Alpha Vantage	No year-ago quarter
Jun 30, 2025Reported Sep 3, 2025	-$1.44Reported	No estimate	$0.00Alpha Vantage	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Prev close: $42.46
52-wk high: $50.16
52-wk low: $14.40
Mkt cap: $1.45B
ROE: -38.8%
P/B: 3.5x
Profit margin: +0.0%
Op margin: +0.0%

Dec 2025 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Dec 2025Mar 2026Jun 2026Sep 2026

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$85.0K	$82.0K	$97.0K	—
Gross profit	-$85.0K	-$82.0K	-$97.0K	—
What it spent
Research and development	$8.5M	$14.6M	$44.1M	$51.5M
Sales and adminSelling, general and administrative	$5.4M	$7.5M	$9.8M	$11.0M
Total operating expenses	$13.9M	$22.0M	$53.8M	$62.5M
What was left
Operating profitOperating income	-$13.9M	-$22.1M	-$53.9M	-$62.5M
Profit before tax	-$11.5M	-$19.1M	-$51.6M	-$59.1M
TaxIncome tax expense	$1.0K	—	—	—
Net profitNet income	-$11.5M	-$19.1M	-$51.6M	-$59.1M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$11.4M	-$19.0M	-$53.8M	-$58.9M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

61balanced

20D volatility

65%annualized

52-week range

$42.46

$14.40$50.16

20D support

$36.03recent floor

20D resistance

$45.78recent ceiling

Returns

5D +11.5%20D +15.7%60D -13.2%

Price vs moving averages

SMA20 +4.8%SMA50 +5.4%SMA200 +26.9%

Volume pace

0.81xvs prior 20D

12 macro signals shaping LBRX right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

-$1.79est. -$1.61

-11.18%

$0.00SEC filing

No year-ago quarter

Jun 30, 2026Aug 11, 2026

-$1.71est. -$0.84

-103.57%

$0.00SEC filing

No year-ago quarter

Mar 31, 2026May 12, 2026

-$0.67est. -$0.70

+3.61%

$0.00SEC filing

No year-ago quarter

Dec 31, 2025Mar 26, 2026

-$0.45est. -$0.32

-40.63%

$0.00Alpha Vantage

No year-ago quarter

Sep 30, 2025Nov 6, 2025

-$0.61est. -$0.28

-117.86%

$0.00Alpha Vantage

No year-ago quarter

Jun 30, 2025Sep 3, 2025

-$1.44Reported

No estimate

$0.00Alpha Vantage

No year-ago quarter

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$0	$0	$0	$0
Cost of what it soldCost of revenue	$85.0K	$82.0K	$97.0K	—
Gross profit	-$85.0K	-$82.0K	-$97.0K	—
What it spent
Research and development	$8.5M	$14.6M	$44.1M	$51.5M
Sales and adminSelling, general and administrative	$5.4M	$7.5M	$9.8M	$11.0M
Total operating expenses	$13.9M	$22.0M	$53.8M	$62.5M
What was left
Operating profitOperating income	-$13.9M	-$22.1M	-$53.9M	-$62.5M
Profit before tax	-$11.5M	-$19.1M	-$51.6M	-$59.1M
TaxIncome tax expense	$1.0K	—	—	—
Net profitNet income	-$11.5M	-$19.1M	-$51.6M	-$59.1M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$11.4M	-$19.0M	-$53.8M	-$58.9M

USD

Dec 2025

Mar 2026

Jun 2026

Sep 2026

What came in

RevenueTotal revenue

Cost of what it soldCost of revenue

$85.0K

$82.0K

$97.0K

—

Gross profit

-$85.0K

-$82.0K

-$97.0K

—

What it spent

Research and development

$8.5M

$14.6M

$44.1M

$51.5M

Sales and adminSelling, general and administrative

$5.4M

$7.5M

$9.8M

$11.0M

Total operating expenses

$13.9M

$22.0M

$53.8M

$62.5M

What was left

Operating profitOperating income

-$13.9M

-$22.1M

-$53.9M

-$62.5M

Profit before tax

-$11.5M

-$19.1M

-$51.6M

-$59.1M

TaxIncome tax expense

$1.0K

—

Net profitNet income

-$11.5M

-$19.1M

-$51.6M

-$59.1M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$11.4M

-$19.0M

-$53.8M

-$58.9M

LB Pharmaceuticals Inc Common Stock

Smart money at a glance

What do analysts expect?

Questions about LBRX filings

Smart money on LBRX

Questions about LBRX filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 11.2% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

LB Pharmaceuticals Inc Common Stock

Smart money at a glance

What do analysts expect?

Questions about LBRX filings

Smart money on LBRX

Questions about LBRX filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 11.2% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

LB Pharmaceuticals Inc Common Stock

Overview

Questions about LBRX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Macro

Ask it in Claude or ChatGPT.

LB Pharmaceuticals Inc Common Stock

Overview

Questions about LBRX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Macro

Ask it in Claude or ChatGPT.